Microsampling to facilitate drug monitoring of oncolytics

Microsampling to facilitate drug monitoring of oncolytics - MSTDM

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57238

Enrollment

225

Registered

2024-06-24

Start date

2025-11-04

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer malignancy cancer

Interventions

blood sampling venous and by fingerprick

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria:Willing and able to provide informed consent;18 years of age or older;Using one or more of the following drugs:CabozantinibPazopanibSunitinibLenvatinibImatinibEnzalutamideAbirateroneEnfortumab vedotinNivolumabIpilimumabPembrolizumabAtezolizumabBevacizumab

Exclusion criteria

Exclusion criteria: Not able to sample themselves using a finger prick

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the method agreement between whole blood sample (WBS) and DBS.	—

Secondary

Measure	Time frame
The secondary endpoints are the success rate of DBS and the difference in SUS score between HemaXis DB 10 and Mitra Clamshell.	—

Countries

Netherlands

Contacts

Public ContactT. Hulle

Leids Universitair Medisch Centrum

T.van_der_Hulle@lumc.nl0715263464

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)